Feb. 3 at 5:28 PM
$LEGN A lot of fucking money could be made here.
Sentiment leans optimistic due to clinical milestones and regulatory tailwinds, but recent news has triggered flat or slightly negative stock moves, with shares trading near 52-week lows and below the 200-day moving average. Q3 2025 earnings showed
$524M in CARVYKTI sales and ~
$1B cash, yet EPS missed estimates slightly (-
$0.05 vs. -
$0.0447).
Analyst Reviews
13 analysts rate LEGN a “Buy” with an average price target of
$64.23 (up to 274% upside from recent levels), ranging from
$21 low to
$90 high.
Earnings Outlook
2025 revenue is forecast at
$1.06B (68% growth from
$627M), rising to
$1.56B in 2026 (48% growth), with EPS improving to -
$0.90 then +
$0.40. Profitability is targeted for 2026 via CARVYKTI sales and margin expansion.
Technicals
Short-term buy signals from moving averages suggest 30% upside potential to
$45-
$58 in 3 months, with support at
$42 and
$37. However, the stock is in a downtrend near its 52-week bottom.
